10.07.14
Charles River Labs’ drug discovery collaboration with AstraZeneca has delivered an undisclosed, oral respiratory candidate for progression into preclinical development.
AstraZeneca and BioFocus, now part of Charles River Discovery Services, have been working collaboratively since March 2012 on a respiratory project, under which BioFocus provided much of the discovery work from its facilities near Cambridge, UK and Leiden, NL. This project has successfully nominated an oral drug candidate for preclinical development.
“We are extremely pleased AstraZeneca chose to partner with Charles River for its early drug discovery work,” said David Smith, corporate vice president, Early Discovery, Charles River. “The recognition this project received from the AstraZeneca Innovative Medicines team is a testament to our collaborative approach to partner programs.”
AstraZeneca and BioFocus, now part of Charles River Discovery Services, have been working collaboratively since March 2012 on a respiratory project, under which BioFocus provided much of the discovery work from its facilities near Cambridge, UK and Leiden, NL. This project has successfully nominated an oral drug candidate for preclinical development.
“We are extremely pleased AstraZeneca chose to partner with Charles River for its early drug discovery work,” said David Smith, corporate vice president, Early Discovery, Charles River. “The recognition this project received from the AstraZeneca Innovative Medicines team is a testament to our collaborative approach to partner programs.”
